John Bradley Sorenson, Executive Vice President of Global Operations at Boston Scientific Corp (NYSE:BSX), recently made significant transactions involving the company's stock. On February 12, ...

So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Boston Scientific, with approximately 10,000 employees in Minnesota, reported a fourth-quarter adjusted net profit of $1 ...

The company expects its 2025 adjusted earnings to be in the range of $2.80 to $2.87 per share, above analysts' average ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024 ...